• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.

作者信息

Hinze L, Möricke A, Zimmermann M, Junk S, Cario G, Dagdan E, Kratz C P, Conter V, Schrappe M, Stanulla M

机构信息

Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany.

出版信息

Leukemia. 2017 Aug;31(8):1840-1842. doi: 10.1038/leu.2017.154. Epub 2017 May 22.

DOI:10.1038/leu.2017.154
PMID:28529312
Abstract
摘要

相似文献

1
Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.在ALL-BFM 95试验中，IKZF1缺失与儿童急性淋巴细胞白血病维持治疗期间长春新碱-地塞米松脉冲治疗相关的预后影响。
Leukemia. 2017 Aug;31(8):1840-1842. doi: 10.1038/leu.2017.154. Epub 2017 May 22.
2
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial.高危儿童急性淋巴细胞白血病诱导后随机分组及延迟强化治疗：国际AIEOP - BFM ALL 2000试验的长期结果
Leukemia. 2020 Jun;34(6):1694-1700. doi: 10.1038/s41375-019-0670-y. Epub 2019 Dec 5.
3
Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.在 AIEOP-BFM ALL 2017 临床试验中，对急性淋巴细胞白血病进行 RNA 测序和 array CGH 的实施。
Ann Hematol. 2020 Apr;99(4):809-818. doi: 10.1007/s00277-020-03953-3. Epub 2020 Feb 20.
4
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.采用强化的急性淋巴细胞白血病（ALL）型疗法且不进行局部放疗的儿童和青少年T细胞淋巴母细胞淋巴瘤患者预后良好。
Ann Hematol. 2001;80 Suppl 3:B73-6. doi: 10.1007/pl00022795.
5
Improved prognosis for childhood acute lymphocytic leukemia with very high white blood cell count (greater than 100/nl) with rotation of non-cross-resistant drug combinations.通过轮换使用非交叉耐药的药物组合，改善白细胞计数非常高（大于100/微升）的儿童急性淋巴细胞白血病的预后。
Haematol Blood Transfus. 1990;33:489-93. doi: 10.1007/978-3-642-74643-7_88.
6
High hyperdiploid acute lymphoblastic leukemia (ALL)-A 25-year population-based survey of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.高超二倍体急性淋巴细胞白血病（ALL）——奥地利ALL-BFM（柏林-法兰克福-明斯特）研究组基于人群的25年调查
Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26327. Epub 2016 Nov 2.
7
Variant translocations of 11q23 in infant acute lymphoblastic leukemia (ALL): do outcomes differ from t(4;11)?婴儿急性淋巴细胞白血病（ALL）中11q23的变异易位：其预后与t(4;11)有差异吗？
Med Pediatr Oncol. 2002 Jul;39(1):63-5. doi: 10.1002/mpo.10047.
8
Increased factor VIII activity and dural sinus thrombosis.因子VIII活性增加与硬脑膜窦血栓形成。
Med Pediatr Oncol. 2002 Jul;39(1):71-2. doi: 10.1002/mpo.1368.
9
[The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].[21世纪，捷克共和国急性淋巴细胞白血病患儿的治愈前景已提高到90%——ALL-IC BFM 2002试验的结果]
Cas Lek Cesk. 2015;154(2):79-89.
10
Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.PETHEMA ALL - 96试验在老年费城染色体阴性急性淋巴细胞白血病患者中的结果。
Eur J Haematol. 2007 Feb;78(2):102-10. doi: 10.1111/j.1600-0609.2006.00778.x. Epub 2006 Nov 6.

引用本文的文献

1
[Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia].[小儿B细胞急性淋巴细胞白血病拷贝数改变的研究进展]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Jun 15;27(6):746-752. doi: 10.7499/j.issn.1008-8830.2501007.
2
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.IKZF1基因改变的异质性与儿童B细胞前体急性淋巴细胞白血病的复发风险
Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02633-3.
3
Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

本文引用的文献

1
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.儿童急性淋巴细胞白血病的治疗：预后因素与临床进展
Curr Hematol Malig Rep. 2016 Oct;11(5):385-94. doi: 10.1007/s11899-016-0337-y.
2
New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.B细胞前体急性淋巴细胞白血病中新出现的预后和预测性遗传生物标志物
Haematologica. 2016 Apr;101(4):407-16. doi: 10.3324/haematol.2015.141101.
3
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.
IKZF1基因改变的异质性与儿童B细胞前体急性淋巴细胞白血病的复发风险
Res Sq. 2024 Nov 11:rs.3.rs-5292018. doi: 10.21203/rs.3.rs-5292018/v1.
4
Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia.IKZF1 缺失在儿童 B 细胞前体急性淋巴细胞白血病中的预后意义和治疗策略。
BMC Cancer. 2024 Aug 29;24(1):1070. doi: 10.1186/s12885-024-12828-z.
5
Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia.B细胞急性淋巴细胞白血病的改变与治疗靶点
Biomedicines. 2024 Jan 1;12(1):89. doi: 10.3390/biomedicines12010089.
6
Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities.在B淋巴细胞白血病中模拟IKZF1损伤揭示了不同的化学敏感性模式和潜在的治疗弱点。
Blood Adv. 2021 Oct 12;5(19):3876-3890. doi: 10.1182/bloodadvances.2020002408.
7
Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations.儿童急性淋巴细胞白血病的多克隆复杂性和亚克隆突变的预后相关性。
Haematologica. 2021 Dec 1;106(12):3046-3055. doi: 10.3324/haematol.2020.259226.
8
IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia.IKAROS 和 CK2 调节高危 B 细胞急性淋巴细胞白血病中 BCL-XL 的表达和化疗敏感性。
Blood. 2020 Sep 24;136(13):1520-1534. doi: 10.1182/blood.2019002655.
9
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?IKZF1 缺失在小儿急性淋巴细胞白血病中的意义：仍然是预后不良的标志吗？
Blood. 2020 Jan 23;135(4):252-260. doi: 10.1182/blood.2019000813.
10
Philadelphia chromosome-like acute lymphoblastic leukemia.费城染色体样急性淋巴细胞白血病
Blood. 2017 Nov 9;130(19):2064-2072. doi: 10.1182/blood-2017-06-743252. Epub 2017 Oct 2.
IKZF1 缺失是儿童 B 细胞前体急性淋巴细胞白血病的独立预后标志物，并可区分在维持治疗期间受益于脉冲治疗的患者：EORTC 儿童白血病组研究 58951 的结果。
Leukemia. 2015 Nov;29(11):2154-61. doi: 10.1038/leu.2015.134. Epub 2015 Jun 8.
4
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.IKZF1 状态作为 BCR-ABL1 阳性儿童 ALL 的预后特征。
Blood. 2014 Mar 13;123(11):1691-8. doi: 10.1182/blood-2013-06-509794. Epub 2013 Dec 23.
5
Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia.断点特异性多重聚合酶链反应可用于检测 B 细胞前体急性淋巴细胞白血病中的 IKZF1 基因内缺失和微小残留病监测。
Haematologica. 2013 Apr;98(4):597-601. doi: 10.3324/haematol.2012.073965. Epub 2012 Oct 12.
6
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.IKZF1 缺失是根据 ALL-BFM 2000 方案治疗的儿童急性淋巴细胞白血病患者结局的独立预测因子。
Haematologica. 2013 Mar;98(3):428-32. doi: 10.3324/haematol.2011.056135. Epub 2012 Aug 8.
7
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.治疗后的分子反应重新定义了儿童和青少年 B 细胞前体急性淋巴细胞白血病的所有预后因素：AIEOP-BFM ALL 2000 研究 3184 例患者的结果。
Blood. 2010 Apr 22;115(16):3206-14. doi: 10.1182/blood-2009-10-248146. Epub 2010 Feb 12.
8
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.IKZF1缺失与急性淋巴细胞白血病的预后
N Engl J Med. 2009 Jan 29;360(5):470-80. doi: 10.1056/NEJMoa0808253. Epub 2009 Jan 7.
9
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.急性淋巴细胞白血病的风险调整治疗可减轻治疗负担并提高生存率：参加ALL-BFM 95试验的2169例未经选择的儿科和青少年患者的治疗结果。
Blood. 2008 May 1;111(9):4477-89. doi: 10.1182/blood-2007-09-112920. Epub 2008 Feb 19.
10
Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.长春新碱和地塞米松脉冲疗法联合强化化疗用于中危急性淋巴细胞白血病儿童：一项多中心随机试验
Lancet. 2007 Jan 13;369(9556):123-31. doi: 10.1016/S0140-6736(07)60073-7.